Arthur He CFA, an analyst from H.C. Wainwright, maintained the Buy rating on Nektar Therapeutics. The associated price target was raised to $135.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arthur He CFA has given his Buy rating due to a combination of factors related to Nektar Therapeutics’ recent clinical trial results and future potential. The company reported promising topline results from its Phase 2b REZOLVE-AA study, which evaluated the drug rezpeg for treating alopecia areata (AA). Despite narrowly missing the primary efficacy endpoint in the full intent-to-treat analysis, a post-hoc analysis excluding certain ineligible patients showed statistically significant results, indicating a stable treatment effect.
Furthermore, the drug demonstrated a durable effect and a favorable safety profile, with low discontinuation rates due to adverse events. The management’s increased probability of launching rezpeg for AA, along with projected risk-adjusted revenues, supports the positive outlook. Consequently, Arthur He has raised the price target for Nektar Therapeutics to $135, reflecting confidence in the company’s potential growth and the successful development of rezpeg.
According to TipRanks, He CFA is a 5-star analyst with an average return of 32.2% and a 52.76% success rate. He CFA covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Vera Therapeutics, and Satellos Bioscience.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $115.00 price target.